Company Profile
Neo-Pharma Biotech Co., Ltd. was established in 2022 by a team of experts in new drug R&D, dedicated to the innovative design and structural optimization of small molecule drugs. We specialize in revitalizing off-patent therapeutics; by employing precise functional group modifications and advanced chemical synthesis, we redesign and optimize these structures to develop novel small molecule drugs with enhanced clinical value.
Guided by our philosophy of “Innovation, Precision, and Evidence-Based” development, Neo-Pharma Biotech integrates cutting-edge chemistry and pharmacology to bridge the gap between drug discovery and clinical application. Our goal is to build an innovative drug platform that combines scientific rigor with industrial competitiveness, delivering safer and more effective therapeutic options for human health.
Our Milestones
Corporate Philosophy
Our Philosophy: Rooted in Integrity
Neo-Pharma Biotech regards integrity and honesty as the bedrock of sustainable growth. We believe that a business built on sincerity is the only way to foster lasting partnerships and earn public trust.
Commitment to Science and Ethics
We insist on transparency and absolute respect for scientific facts in our R&D and operations. By holding ourselves to the highest professional ethics, we aim to advance the biotech industry and safeguard human health.
Looking Forward
Integrity is our cornerstone. It guides us as we drive innovative research and deepen our expertise, ensuring we deliver safe, effective, and high-value medical solutions to the world.
Core Team
CEO & Founder
Dr. Edward Lin
- CEO of NEO-Pharma Biotech
- PhD Researcher of Formerly Taiwan The Genomics Research Center, Academia Sinica
- PhD of Taiwan Tsinghua University, Institute of Bioinformatics and Structural Biology, College of Life Science
Honorary Vice Chairman
Dr. Andrew H.-J. Wang
- Former Vice President of Academia Sinica
- Distinguished Visiting Scholar of IBC, Academia Sinica
- Distinguished Visiting Chairs of BioTReC, Academia Sinica
- Past-President of IUBMB
- Chair Professor of PhD Program for Translational Medicine, CoMST, Taipei Medical University
Chief Medical Officer
Dr. Daphne Shen
- Clinical Research Director of StatPlus CRO
- Medical Director of Adimmune Corporation
- Attending Physician of Chang Gung Memorial Hospital, Kaohsiung
Chief Consultant
Dr. Sherry Ku
- President of Kuder Consulting Inc.
- Former Chairman of Active Pharmaceutical. Ingredients (current Savior Lifetec Co.)
- Former President & CTO of TWI PHARMACEUTICALS, INC.
- Former R&D Director of Wyeth
Chief Financial Officer
Eliot Wu
- Independent Director of ALCOR MICRO
- Independent Director of ENE Technology
- Independent Director of SYNIC
- Former Chairman of Cathay Securities Corporation
Director/CEO
Neo-Pharma Innovation U.S.
Dr. Minyi Shi
- Executive MBA Business of UCLA Anderson School of Management
- PhD of Penn State Great Valley, Electrical and Electronics Engineering
- Chair of Due Committee and Member of Executive Committee of TCA Los Angeles
- Executive Director of TeaLa
- Business Advisor of TINVA
